Tryptamine Therapeutics (ASX:TYP) Total Stockholders Equity : A$2.72 Mil (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Tryptamine Therapeutics Total Stockholders Equity?

Tryptamine Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was A$2.72 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Tryptamine Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 was A$0.02. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Tryptamine Therapeutics's Debt-to-Equity for the quarter that ended in Dec. 2023 was 0.00.

Tryptamine Therapeutics Total Stockholders Equity Historical Data

The historical data trend for Tryptamine Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tryptamine Therapeutics Total Stockholders Equity Chart

Tryptamine Therapeutics Annual Data

Trend

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Total Stockholders Equity

Get a 7-Day Free Trial

5.12

5.02

18.87

8.81

4.13

Tryptamine Therapeutics Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Stockholders Equity	Get a 7-Day Free Trial						11.31	8.81	4.39	4.13	2.72

Tryptamine Therapeutics (ASX:TYP) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Tryptamine Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(2.715	-	0)	/	175.769
	=	0.02

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Tryptamine Therapeutics's Debt-to-Equity for the quarter that ended in Dec. 2023 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	2.715
	=	0.00

Tryptamine Therapeutics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Tryptamine Therapeutics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Tryptamine Therapeutics (ASX:TYP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tryptamine Therapeutics Ltd (ASX:TYP) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

697 Burke Road, Suite 201, Camberwell, VIC, AUS, 3124

Website

https://www.exopharm.com

Exopharm Ltd is a biopharmaceutical company that engages in the development of regenerative medicine in Australia. The company is engaged in developing and commercializing exosomes as therapeutic agents. The company operates in one segment namely the research and development of biopharmaceutical drugs. Revenue is generated from Australia.

Tryptamine Therapeutics (ASX:TYP) Headlines

No Headlines